AN2 Therapeutics Inc (NASDAQ: ANTX) is -94.58% lower on its value in year-to-date trading and has touched a low of $0.87 and a high of $22.22 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ANTX stock was last observed hovering at around $1.10 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $1.11, the stock is -41.02% and -49.16% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.51 million and changing 0.91% at the moment leaves the stock -86.10% off its SMA200. ANTX registered -92.03% loss for a year compared to 6-month loss of -66.47%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -58.11% gain in the last 1 month and extending the period to 3 months gives it a -47.64%, and is 8.82% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.63% over the week and 10.94% over the month.
AN2 Therapeutics Inc (ANTX) has around 41 employees, a market worth around $33.12M and $0.00M in sales. Distance from 52-week low is 27.59% and -95.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-65.74%).
The EPS is expected to grow by 28.01% this year
59.0 institutions hold shares in AN2 Therapeutics Inc (ANTX), with institutional investors hold 97.56% of the company’s shares. The shares outstanding are 29.74M, and float is at 19.38M with Short Float at 3.53%. Institutions hold 72.82% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 5.55 million shares valued at $11.94 million. The investor’s holdings represent 18.6515 of the ANTX Shares outstanding. As of 2024-06-30, the second largest holder is OCTAGON CAPITAL ADVISORS LP with 3.22 million shares valued at $6.92 million to account for 10.8196 of the shares outstanding. The other top investors are FRAZIER LIFE SCIENCES MANAGEMENT, L.P. which holds 2.09 million shares representing 7.0183 and valued at over $4.49 million, while TCG CROSSOVER MANAGEMENT, LLC holds 5.225 of the shares totaling 1.56 million with a market value of $3.34 million.
AN2 Therapeutics Inc (ANTX) Insider Activity
Still, SEC filings show that on Aug 14 ’24, Leonard Braden Michael (10% Owner) acquired 1,500,000 shares at an average price of $1.04 for $1.56 million. The insider now directly holds 5,749,432 shares of AN2 Therapeutics Inc (ANTX).
